Healthcare provider profile · identity verified

Christopher Garcia, MD

Allopathic & Osteopathic Physicians|Family Medicine · ZEPHYRHILLS, FL · NPI 1881607109

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Christopher Garcia, MD received $358.96 in general payments during 2025 across 5 reported records.

Corcept Therapeutics accounted for 63.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$358.96

5 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Corcept Therapeutics	Unresolved — no canonical attribution shown	$228.03	63.5%	2	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$91.58	25.5%	1	2025
Amgen Inc.	Unresolved — no canonical attribution shown	$21.07	5.9%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$18.28	5.1%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$358.96	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Korlym Normalized: korlym	Drug	Corcept Therapeutics	$228.03	2	2025
Source payment records 2025-06-03 · Corcept Therapeutics · $113.03 · Open Payments source 2025-10-16 · Corcept Therapeutics · $115.00 · Open Payments source
JARDIANCE Normalized: jardiance	Drug	Lilly USA, LLC	$91.58	1	2025
Source payment records 2025-05-13 · Lilly USA, LLC · $91.58 · Open Payments source
OTEZLA Normalized: otezla	Drug	Amgen Inc.	$21.07	1	2025
Source payment records 2025-08-25 · Amgen Inc. · $21.07 · Open Payments source
REPATHA Normalized: repatha	Biological	Amgen Inc.	$21.07	1	2025
Source payment records 2025-08-25 · Amgen Inc. · $21.07 · Open Payments source
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$18.28	1	2025
Source payment records 2025-04-28 · Novo Nordisk Inc · $18.28 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	16 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	725	195
Amlodipine Besylate	Amlodipine Besylate	482	142
Gabapentin	Gabapentin	439	117
Lisinopril	Lisinopril	399	118
Omeprazole	Omeprazole	395	116
Levothyroxine Sodium	Levothyroxine Sodium	340	91
Metformin Hcl	Metformin Hcl	340	91
Tramadol Hcl	Tramadol Hcl	283	89
Rosuvastatin Calcium	Rosuvastatin Calcium	250	70
Glimepiride	Glimepiride	247	61
Hydrochlorothiazide	Hydrochlorothiazide	243	74
Simvastatin	Simvastatin	223	68
Celecoxib	Celecoxib	219	65
Alprazolam	Alprazolam	218	37
Albuterol Sulfate Hfa	Albuterol Sulfate	210	61
Losartan Potassium	Losartan Potassium	210	59
Methylprednisolone	Methylprednisolone	209	155
Citalopram Hbr	Citalopram Hydrobromide	202	57
Tamsulosin Hcl	Tamsulosin Hcl	201	56
Furosemide	Furosemide	200	66
Pravastatin Sodium	Pravastatin Sodium	188	57
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	172	45
Pantoprazole Sodium	Pantoprazole Sodium	156	49
Baclofen	Baclofen	154	46
Duloxetine Hcl	Duloxetine Hcl	148	44
Potassium Chloride	Potassium Chloride	148	44
Carvedilol	Carvedilol	145	40
Metoprolol Tartrate	Metoprolol Tartrate	135	35
Metoprolol Succinate	Metoprolol Succinate	130	38
Warfarin Sodium	Warfarin Sodium	128	29
Trazodone Hcl	Trazodone Hcl	127	31
Lovastatin	Lovastatin	117	36
Alendronate Sodium	Alendronate Sodium	116	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	115	33
Azithromycin	Azithromycin	114	99
Sildenafil Citrate	Sildenafil Citrate	105	25
Sertraline Hcl	Sertraline Hcl	103	33
Temazepam	Temazepam	102	11
Metformin Hcl Er	Metformin Hcl	101	33
Montelukast Sodium	Montelukast Sodium	100	29
Fluticasone Propionate	Fluticasone Propionate	99	39
Allopurinol	Allopurinol	97	27
Ciprofloxacin Hcl	Ciprofloxacin Hcl	96	78
Novolin N	Insulin Nph Human Isophane	93	25
Clopidogrel	Clopidogrel Bisulfate	92	28
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	90	31
Naproxen	Naproxen	87	25
Triamcinolone Acetonide	Triamcinolone Acetonide	80	31
Tizanidine Hcl	Tizanidine Hcl	74	15
Eliquis	Apixaban	72	15
Glipizide	Glipizide	69	18
Meloxicam	Meloxicam	68	20
Ezetimibe	Ezetimibe	67	22
Clonidine Hcl	Clonidine Hcl	65	20
Donepezil Hcl	Donepezil Hcl	65	20
Oxybutynin Chloride	Oxybutynin Chloride	65	16
Fluoxetine Hcl	Fluoxetine Hcl	60	12
Fenofibrate	Fenofibrate	58	18
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	55	suppressed
Novolin R	Insulin Regular, Human	55	12
Atenolol	Atenolol	54	16
Dropsafe Prep Pads	Alcohol Antiseptic Pads	54	18
Oxycodone Hcl	Oxycodone Hcl	51	11
Buspirone Hcl	Buspirone Hcl	47	15
Cefdinir	Cefdinir	47	36
Diclofenac Sodium	Diclofenac Sodium	47	13
Morphine Sulfate Er	Morphine Sulfate	47	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	47	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	46	11
Wixela Inhub	Fluticasone Propion/Salmeterol	46	suppressed
Clonazepam	Clonazepam	45	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	45	39
Ketoconazole	Ketoconazole	45	17
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	45	suppressed
Pregabalin	Pregabalin	45	13
Prednisone	Prednisone	44	22
Finasteride	Finasteride	43	12
Nebivolol Hcl	Nebivolol Hcl	43	13
Meclizine Hcl	Meclizine Hcl	40	15
Vitamin D2	Ergocalciferol (Vitamin D2)	40	13
Famotidine	Famotidine	39	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	12
Droplet Insulin Syringe	Syringe And Needle,insulin,1ml	37	11
Escitalopram Oxalate	Escitalopram Oxalate	36	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	34	15
Primidone	Primidone	34	suppressed
Amiodarone Hcl	Amiodarone Hcl	33	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	33	suppressed
Ibuprofen	Ibuprofen	33	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	33	suppressed
Diazepam	Diazepam	32	suppressed
Hydralazine Hcl	Hydralazine Hcl	32	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	11
Hydroxyzine Hcl	Hydroxyzine Hcl	30	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	29	suppressed
Topiramate	Topiramate	29	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	28	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	27	suppressed
Benazepril Hcl	Benazepril Hcl	27	suppressed
Cephalexin	Cephalexin	27	21
Metronidazole	Metronidazole	27	19
Ibu	Ibuprofen	26	suppressed
Spironolactone	Spironolactone	26	suppressed
Xarelto	Rivaroxaban	26	suppressed
Promethazine Hcl	Promethazine Hcl	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Glipizide Er	Glipizide	22	suppressed
Novolin N Flexpen	Insulin Nph Human Isophane	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Enalapril Maleate	Enalapril Maleate	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	20	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	19	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	19	suppressed
Morphine Sulfate	Morphine Sulfate	17	suppressed
Novolin R Flexpen	Insulin Regular, Human	17	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	suppressed
Testosterone Cypionate	Testosterone Cypionate	17	suppressed
Gemfibrozil	Gemfibrozil	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Terazosin Hcl	Terazosin Hcl	16	suppressed
Methimazole	Methimazole	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Estradiol	Estradiol	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Mupirocin	Mupirocin	13	11
Ramipril	Ramipril	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Droplet Insulin Syringe	Syrge-Ndl,ins 0.5 Ml Half Mark	12	suppressed
Fluorouracil	Fluorouracil	12	suppressed
Glyburide	Glyburide	12	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Benztropine Mesylate	Benztropine Mesylate	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Clotrimazole	Clotrimazole	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Lacosamide	Lacosamide	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Novolog	Insulin Aspart	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$358.96 · 5 records	Corcept Therapeutics	JARDIANCE, Korlym, OTEZLA, REPATHA, Wegovy	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error